Treating Dermatology Patients with Off-Label JAK Inhibitors: An Interview with Gabriela Maloney, DO
In this insightful interview, Gabriela Maloney, DO, discusses the innovative use of off-label JAK inhibitors in dermatology at the SDPA Fall Conference. Maloney highlights the potential of these drugs to revolutionize treatment for various inflammatory skin conditions.
Maloney begins by addressing the limitations of traditional immunosuppressants, which often require extensive monitoring and carry potential side effects. She explains, "We're often giving [patients] immunosuppressants that require a lot of lab monitoring, a lot of drug interactions, a lot of potential side effects, and they're making people feel slightly better, but not completely clear."
The key to JAK inhibitors lies in their ability to target the JAK-STAT pathway, a critical component of inflammation. Maloney emphasizes, "By inhibiting JAKs, we're really kind of toning down the volume of inflammation, but in a very targeted way. We're not wiping out the immune system. We're not depleting their white cells, T cells, or B cells. We really are just dialing down that volume knob a little bit lower."
Several JAK inhibitors, such as upadacitinib, baricitinib, abrocitinib, and deucravacitinib, have recently received FDA approval in the US. Maloney provides an in-depth overview of their mechanism of action during her talk at SDPA, offering valuable insights into their implementation for various inflammatory conditions.
She mentions ongoing phase 3 and 2 trials for vitiligo and hidradenitis suppurativa, chronic conditions with limited treatment options. Additionally, she discusses bullous diseases like bullous pemphigoid, pemphigus vulgaris, lichen planus erosive lichen planus, and cicatricial alopecia, for which JAK inhibitors show promise.
One of the most exciting discoveries, according to Maloney, is the overlap in inflammatory pathways. She notes, "What is being discovered is information regarding overlapping inflammatory pathways." Furthermore, she highlights the encouraging observation of hair regrowth in individuals with cicatricial alopecia.
For those interested in learning more about the dermatology topics presented at the 2025 SDPA Fall Conference, the latest conference coverage on the website provides valuable insights. Maloney's interview offers a glimpse into the potential of off-label JAK inhibitors to transform dermatology treatment, sparking curiosity and further exploration in the field.
This session summary includes edited quotes for clarity and conciseness.
